Last reviewed · How we verify
dexlansoprazole based triple therapy
Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking H+/K+-ATPase in parietal cells; in triple therapy it is combined with antibiotics to eradicate Helicobacter pylori infection.
Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking H+/K+-ATPase in parietal cells; in triple therapy it is combined with antibiotics to eradicate Helicobacter pylori infection. Used for Helicobacter pylori eradication as part of triple therapy, Peptic ulcer disease associated with H. pylori infection.
At a glance
| Generic name | dexlansoprazole based triple therapy |
|---|---|
| Also known as | Dexilant-based triple therapy |
| Sponsor | Kaohsiung Medical University |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Dexlansoprazole reduces intragastric acid production, creating an environment where antibiotics (typically amoxicillin and clarithromycin or metronidazole) can more effectively eliminate H. pylori bacteria. The combination therapy addresses both acid suppression and bacterial eradication, improving cure rates for peptic ulcer disease and H. pylori-associated conditions.
Approved indications
- Helicobacter pylori eradication as part of triple therapy
- Peptic ulcer disease associated with H. pylori infection
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Taste disturbance
Key clinical trials
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection (PHASE3)
- Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy (PHASE4)
- Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)
- Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management (PHASE4)
- Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication (PHASE3)
- Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication. (PHASE4)
- Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |